
Solid tumours - NTRK gene fusion positive program in Pharmaceutical Benefits Scheme (PBS) 012-22062457

-   Background
-   Process
-   Resources

[Expand/Collapse all sections]Expand all

This document outlines details of PBS-subsidised larotrectinib for
patients with solid tumours that are confirmed to be neurotrophic
tropomyosin receptor kinase (NTRK) gene fusion positive.

Solid tumours - NTRK gene fusion positive and listing dates

NTRK gene fusion positive solid tumours is a condition in patients where
a gene fusion results in the development and growth of solid tumours in
a variety of tissue types.

Listing dates are:

-   larotrectinib – 1 July 2022

For more information, see Written Authority Required Drugs.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex
Drugs Programs team and choose the option relevant to the condition
treated.

The Resources page contains links to application forms, contact details,
item and restriction codes, the PBS schedule and the Services Australia
website.

Related links

Contacting a Health Service Delivery Division Programme Support Officer
(PSO)

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA
System)

Process telephone Authority approval application

Processing and National Demand Allocation (PaNDA)

Processing written authority approval requests

Processing Written Authority Required Listings

Work Optimiser for staff

Written Authority Required Drugs

                                   

-   Services Australia ABN 90 794 605 008 
